Extended Data Fig. 1: In vivo models of chemotolerance in TNBC.
From: H3K27me3 conditions chemotolerance in triple-negative breast cancer
a. Graph of the relative tumor volumes over time (days) for PDX_95 for eight mice treated with a first round of Capecitabine. b. (Left) UMAP representation of scRNA-seq datasets, colored according to RNA-inferred cluster IDs. (Right) Histogram of the frequency of each expression cluster in the indicated samples. c. Barplot displaying the top 5 pathways activated in persister cells. d. UMAP representation of scRNA-seq datasets, colored according to log2 expression signals for persister genes, log2FC and q-values are indicated above the graph. e. Histogram of the proportion of cells in the different cell cycle phases based on expression of cell cycle in the scRNA-seq datasets. Proportions in each sample were compared to untreated sample using two-sided Fisher’s exact test, p-values are indicated. f. Graph of the relative tumor volumes over time (days) for PDX_39 for fourteen mice treated with capecitabine and three untreated mice. g. UMAP representation of scRNA-seq datasets, colored according to sample ID. h. UMAP representation of scRNA-seq datasets, colored according to expression clusters. i. Barplot displaying the top 5 pathways activated in persister cells. j. UMAP representation of scRNA-seq datasets, colored according to log2 expression signals for persister genes, log2FC and q-values are indicated above the graph. k. Histogram of the proportion of cells in the different cell cycle phases based on expression of cell cycle in the scRNA-seq datasets. Proportions in persister sample were compared to untreated sample using a two-sided Fisher exact test, p-value are indicated. l-q as (f-k) for PDX_172.
